Cart
sales@molnova.com
Ermanin
CAS No. 20869-95-8
Ermanin( —— )
Catalog No. M30895 CAS No. 20869-95-8
Ermanin is a flavonoid isolated from Tanacetum microphyllum.Ermanin inhibits platelet aggregation and has anti-tuberculosis and anti-viral/bacterial properties.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 302 | In Stock |
|
| 2MG | 174 | In Stock |
|
| 5MG | 282 | In Stock |
|
| 10MG | 471 | In Stock |
|
| 25MG | 848 | In Stock |
|
| 50MG | 1097 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameErmanin
-
NoteResearch use only, not for human use.
-
Brief DescriptionErmanin is a flavonoid isolated from Tanacetum microphyllum.Ermanin inhibits platelet aggregation and has anti-tuberculosis and anti-viral/bacterial properties.
-
DescriptionErmanin is a flavonoid isolated from Tanacetum microphyllum.Ermanin inhibits platelet aggregation and has anti-tuberculosis and anti-viral/bacterial properties.Ermanin has anti-inflammatory activity by inhibiting the expression of iNOS and COX-2.Ermanin may have anti-HIV-1 activity. Ermanin is effective in inhibiting Dione juno larvae at lower concentrations.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number20869-95-8
-
Formula Weight314.3
-
Molecular FormulaC17H14O6
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Isoliquiritin
Isoliquiritin, liquiritin and isoliquirigenin inhibits the p53-dependent pathway and shows crosstalk between Akt activities.
-
Cholecystokinin-33 (...
Cholecystokinin-33 (1-21) (porcine)
-
Letaplimab
Letaplimab (IBI-188) is a humanized IgG4 class antibody targeting CD47 and is often used in combination with azacitidine for the treatment of primary diagnosis of intermediate- to high-risk myelodysplastic syndromes.
